Document Detail

Optimizing reperfusion in patients with STEMI: a critical evaluation of pharmacologic and non-pharmacologic strategies.
MedLine Citation:
PMID:  24043331     Owner:  NLM     Status:  MEDLINE    
Among patients with ST-elevation myocardial infarction (STEMI), rapidly re-establishing normal coronary blood flow is of paramount importance. More than 25 % of hospitals in the USA do not have access to timely primary percutaneous coronary intervention, highlighting the need for clinicians to understand both pharmacologic and non-pharmacologic strategies for STEMI. This manuscript reviews the current state of the art in STEMI care, describing both pharmacologic and non-pharmacologic strategies for reperfusion.
Xiaoyu Yang; Duane S Pinto; Anjan K Chakrabarti
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article; Review    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  13     ISSN:  1179-187X     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-11-22     Completed Date:  2014-07-10     Revised Date:  2014-10-22    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  399-406     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon, Coronary / methods,  standards*
Fibrinolytic Agents / therapeutic use
Myocardial Infarction / therapy*
Myocardial Reperfusion / methods,  standards*
Randomized Controlled Trials as Topic / methods,  standards
Thrombolytic Therapy / methods,  standards*
Time-to-Treatment / standards,  trends
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arteriovenous fistula creation using the Optiflow™ vascular anastomotic connector: the OPEN (Optiflo...
Next Document:  A knockdown mutation of YELLOW-GREEN LEAF2 blocks chlorophyll biosynthesis in rice.